Home - Products - Antibodies - Primary Antibodies - Polyclonal Antibody - Details

Rabbit Anti-PARK2 Polyclonal Antibody#abs135670

Please note that the price mentioned above is solely for your reference. For a detailed price, we kindly request you to get in touch with our seller, Vecent. Western blot analysis of PC12 cell and braincell lysate using PARK2 antibody. This product is for research use only, not for use in...

Send Inquiry

Description

Catalog-specification	Delivery time	USD price
abs135670-100ug	1-2 Weeks	301.0
abs135670-50ug	1-2 Weeks	201.0

Please note that the price mentioned above is solely for your reference. For a detailed price, we kindly request you to get in touch with our seller, Vecent.

Overview
catalog	abs135670
Description	The protein Parkin comprises 465 amino acids and contains an amino-terminal ubiquitin domain as well as a carboxy-terminal RING-box. In the context of AR-JP, it has been discovered that deletions located in the gene on chromosome 6 that encodes Parkin are responsible for this condition.
Other names	Parkin, also known as E3 ubiquitin ligase or E3 ubiquitin-protein ligase, is a protein that is encoded by the PRKN gene. It is a crucial player in the development of Parkinson's disease, particularly the autosomal recessive juvenile type. Parkin functions as an E3 ubiquitin ligase, which means that it is responsible for tagging specific proteins for degradation by the cell's machinery. It accomplishes this through a process called ubiquitination, which involves adding the small protein ubiquitin to the target protein. Mutations in the PRKN gene can lead to a malfunctioning parkin protein, which in turn can result in the accumulation of damaged proteins within cells. This buildup of protein aggregates is a hallmark of Parkinson's disease, and causes the degeneration of dopaminergic neurons in the brain. Several other names have been attributed to parkin, including FRA6E, LPRS 2, LPRS2, PARK 2, Park2, Parkinson disease protein 2, Parkinson juvenile disease protein 2, and Ubiquitin E3 ligase PRKN. However, no matter what it is called, this crucial protein remains a key target for scientists seeking to find a cure for Parkinson's disease.
Source	Rabbit
Specificity	The PARK2 Antibody is capable of detecting total PARK2 levels in the body. It specifically targets endogenous levels of the protein and can provide accurate results. This antibody is a reliable tool for researchers and clinicians who are investigating the role of PARK2 in various diseases and conditions. With its high specificity and sensitivity, this antibody can be used for a variety of applications, including immunohistochemistry and Western blotting. Overall, the PARK2 Antibody is a valuable resource for those working in the field of Parkinson's disease and neurodegeneration.
Species Reactivity	Human;Mouse;Rat
Antigen	PARK2
Application	For western blotting, you can use a dilution range of 1:500 to 1:2000. As for immunohistochemistry, a dilution range of 1:50 to 1:200 is recommended. And finally, for ELISA using peptide, the suitable dilution range would be 1:20000 to 1:40000. Please note that these dilution ranges are based on the original text information and may differ depending on your specific experiment. Be sure to refer to the manufacturer's instructions and optimize your dilution accordingly.
Immunogen	A synthesized peptide derived from human PARK2.
MW	52kDa
Properties
Concentration	1mg/ml
purification	SulfoLink™ Coupling Resin was employed in the purification process of the antiserum through peptide affinity chromatography. Let me generate another similar content by rephrasing the initial information while preserving its original meaning.
Clonality	Polyclonal Antibody
Stability & Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles
Storage buffer	Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt.
Target
Background	Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPT5, TOMM20, USP30, ZNF746 and AIMP2 (PubMed:10973942, PubMed:10888878, PubMed:11431533, PubMed:12150907, PubMed:12628165, PubMed:16135753, PubMed:21376232, PubMed:23754282, PubMed:23620051, PubMed:24660806, PubMed:24751536). Mediates monoubiquitination as well as 'Lys-6', 'Lys-11', 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context (PubMed:19229105, PubMed:20889974, PubMed:25621951). Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation (PubMed:17846173, PubMed:19229105). Mediates 'Lys-63'-linked polyubiquitination of a 22 kDa O-linked glycosylated isoform of SNCAIP, possibly playing a role in Lewy-body formation (PubMed:11590439, PubMed:11431533, PubMed:19229105, PubMed:11590439, PubMed:15728840). Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy (PubMed:20889974). Promotes the autophagic degradation of dysfunctional depolarized mitochondria (mitophagy) by promoting the ubiquitination of mitochondrial proteins such as TOMM20, RHOT1/MIRO1 and USP30 (PubMed:19029340, PubMed:19966284, PubMed:23620051, PubMed:24896179, PubMed:25527291). Preferentially assembles 'Lys-6'-, 'Lys-11'- and 'Lys-63'-linked polyubiquitin chains following mitochondrial damage, leading to mitophagy (PubMed:25621951). Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in the regulation of neuron death (PubMed:21376232). Limits the production of reactive oxygen species (ROS). Regulates cyclin-E during neuronal apoptosis. In collaboration with CHPF isoform 2, may enhance cell viability and protect cells from oxidative stress (PubMed:22082830). Independently of its ubiquitin ligase activity, protects from apoptosis by the transcriptional repression of p53/TP53 (PubMed:19801972). May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity (PubMed:11439185). May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. May represent a tumor suppressor gene.
Tissue specificity	Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis. Found in serum (at protein level).
Posttranslational modification	Auto-ubiquitinates in an E2-dependent manner leading to its own degradation (PubMed:19229105). Also polyubiquitinated by RNF41 for proteasomal degradation.S-nitrosylated. The inhibition of PRKN ubiquitin E3 ligase activity by S-nitrosylation could contribute to the degenerative process in PD by impairing the ubiquitination of PRKN substrates.Phosphorylation at Ser-65 by PINK1 contributes to activate PRKN activity. It is however not sufficient and requires binding to phosphorylated ubiquitin as well.
Celluar localization	Cytosol;Endoplasmic reticulum;Golgi apparatus;Mitochondrion;Nucleus;
UniPort	O60260